• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Sun Pharma Offers Full Buyout of Taro


Israeli pharmaceutical organization expected to evaluate the offer.

Pharma Stocks Medical Health Care Market Ticker Boxes 3d Illustration. Image Credit: Adobe Stock Images/iQoncept

Image Credit: Adobe Stock Images/iQoncept

Sun Pharma, an Indian pharmaceutical company, has offered to take full control of Taro pharmaceuticals for $38 a share. Reportedly, the Israeli-based company has formed a special committee to evaluate the offer after its shares went up 25 percent.

As per the terms of a potential deal, it would be an all-cash transaction, effectively giving full stock control to Sun Pharma.

According to a filing by Sun Pharma to the stock exchanges, the company “envisages the proposed transaction to be consummated in the form of a reverse triangular merger under the Israeli Companies Law, 1999 ("ICL") and practice. In this context, Purchaser shall form a wholly owned subsidiary (the "SPV"), which shall enter into a merger agreement with Taro, with the SPV merging with and into Taro and Taro surviving the merger transaction. Consequently, Taro shall become a wholly owned subsidiary of Purchaser and be de-listed from NYSE."

Reference: Sun Pharma sets sights on remaining stake in Taro for $38 per share. May 29, 2023/Money Control

Related Videos
Related Content